Alerta

Anti-Peripheral Lymph Node Addressin Antibodies and Uses Thereof

Resumen de: US2025197508A1

The present disclosure provides, inter alia, anti-peripheral lymph node address in antibodies and antigen binding fragments thereof. The present disclosure also provides compositions comprising drug-containing polymeric particles that mimic lymphocyte migration in vivo and can specifically deliver immunosuppressive or immunoregulatory drugs to lymphoid tissues and sites of chronic inflammation where T-cell activation and T-cell mediated injury are occurring; such compositions comprise the antibodies or antigen-binding fragments thereof described in the disclosure. The present disclosure also comprises antibody-drug conjugates and compositions comprising the antibody-drug conjugates. Methods of preparing and using these antibodies, antigen-binding fragments thereof, and compositions thereof are also provided.

TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR

Resumen de: US2025197463A1

The present invention provides, among other things, an improved method of treating cystic fibrosis (CF) in a human subject. The method comprises administering a composition comprising an mRNA encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein at a concentration of 0.5 mg/mL or greater to a human subject via nebulization. The composition is aerosolized using a nebulizer and a nominal dose of the mRNA is administered to the human subject via the nebulizer over a period of time, typically at least 30 minutes, at a suitable nebulization rate, e.g., at least 0.2 mL/minute.

Acid Degradable Solid Lipid Nanoparticles

Resumen de: US2025197348A1

Acid degradable solid lipid nanoparticles comprise PEG conjugated to cholesterol via an acid degradable linkage comprising an azide-benzaldehyde acetal.

GLYCOMIMETIC LIGANDS

Resumen de: US2025195689A1

Described herein are glycan compounds and particles comprising glycan compounds. The compounds and particles described herein are useful in methods of treating immune and inflammatory-related diseases. or a pharmaceutically acceptable salt thereof

GAS NANO/MICRO-BUBBLE COMPOSITIONS AND USES THEREOF

Resumen de: US2025195698A1

Provided herein are gas bubble populations optimized for certain imaging and therapeutic ultrasound uses, methods of preparing such populations, and methods of use thereof.

Multiplexed Analysis of Materials for Tissue Delivery

Resumen de: US2025195688A1

Disclosed herein are compositions and methods for identifying materials suitable for functional delivery of a bioactive agent to a target tissue. These compositions and methods have the advantage of simultaneously screening a library of materials for the ability to deliver a bioactive agent to a cell, tissue, or organ. The compositions and methods can also be used to confirm that the agent is delivered in a manner sufficient for function of the agent.

HUMANIZED ANTI-CD8 ANTIBODIES AND USES THEREOF

Resumen de: US2025195685A1

The present disclosure provides humanized antibodies and antigen binding domains thereof that bind CD8α and other antibody formats comprising these antigen binding domains, their use as a targeting moiety on lipid nanoparticles (tLNP) to deliver a therapeutic payload (such as a nucleic acid molecule) or other types of payloads. The present disclosure further relates to pharmaceutical compositions comprising the humanized anti-CD8α antibodies and CD8-targeted tLNP encapsulating a payload.

COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY

Resumen de: US2025195676A1

Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

METFORMIN NANOFORMULATIONS AND METHODS OF USE THEREOF

Resumen de: US2025195670A1

The present invention provides metformin nanoparticles and methods of use thereof.

SYNTHETIC PLATELETS

Resumen de: US2025195621A1

A synthetic platelet including a biocompatible flexible nanoparticle, the nanoparticle having an outer surface and a plurality of site targeted peptides conjugated to the surface, the synthetic platelet also including a therapeutic agent, wherein the therapeutic agent is encapsulated by the nanoparticle, wherein the synthetic platelet adheres to the site targeted and promotes delivery of the therapeutic agent onto sites of the synthetic platelet adhesion, and wherein the therapeutic agent is released at the site targeted via a site-relevant enzyme.

IMMUNOTHERAPEUTIC CONSTRUCTS AND METHODS OF THEIR USE

Resumen de: US2025195641A1

Disclosed herein are immunotherapeutic constructs comprising a delivery particle, at least one adjuvant, and one or more therapeutic agents/compounds that cause antigen release and/or modulate immunosuppressive tumor microenvironment. These immunotherapeutic constructs create adaptive immunity or anti-cancer immune response(s) that can be used, for instance, to prevent and treat broad types of cancer. Further disclosed are uses of the immunotherapeutic constructs, including to prevent and treat cancer in humans and animals.

MULTI-EPITOPE MRNA SARS-COV-2 VACCINE FOR BOOSTING IMMUNITY THROUGH THE ACTIVATION OF CD4 AND CD8 T CELLS AS WELL AS B LYMPHOCYTES

Resumen de: US2025195639A1

In various embodiments immunogenic nanoparticles are provided that are capable of raising an immune response directed against SARS-CoV-2. In certain embodiments the immunogenic nanoparticles comprise mRNA multi-epitope vaccines that can be used in combination with or independent of other covid-19 vaccines (e.g., the spike protein mRNA vaccine(s)) to invoke a strong CD8+ or CD4+ T-cell as well as neutralizing antibody producing B-cell responses. In certain embodiments this vaccine is based on the rational combination of well-conserved T- and B-cell epitopes identified COVID-19 and viral variants.

LIPID NANOPARTICLES USED TO TRANSPORT NUCLEIC ACIDS INTO LYMPHATIC ENDOTHELIUM CELLS

Resumen de: US2025197852A1

The present invention provides a lipid nanoparticle used for delivering a nucleic acid to a lymphatic endothelial cell, including an ionic lipid represented by the formula (1), cholesterol, and a dimyristoylglycerol PEG with a number average molecular weight of PEG chain of 1,000 to 3,000, wherein an amount of the dimyristoylglycerol PEG is not less than 3 mol % with respect to the total of the ionic lipid represented by the formula (1) and the cholesterol (the symbols in the formula (1) are as defined in the specification).

POLYMER-COATED NANOPARTICLES

Resumen de: US2025195442A1

The invention is in the field of nanoparticles. In particular, the invention relates to a polymer-coated nanoparticle comprising a biologically active payload. The invention further relates to a method to prepare the polymer-coated nanoparticle. The polymer-coated nanoparticles may be used as a medicament, preferably as a vaccine, such as a prophylactic and/or a therapeutic vaccine.

NIR-responsive stem cell-derived inflammation attenuating complex and use thereof

Resumen de: US2025195661A1

Provided is an inflammation attenuating complex, which uses infrared-responsive photothermal stem cells that effectively treat inflammatory diseases by efficiently delivering anti-inflammatory drugs to the site of inflammation due to enhanced migration ability to the site of inflammation in the body, and a use thereof.

CATIONIC LIPID

Resumen de: US2025197343A1

The present invention provides a technique capable of transferring an active ingredient, particularly, a nucleic acid, to a cell with excellent efficiency and/or to various cells and a cationic lipid for use in this technique, etc. The cationic lipid of the present invention is a compound represented by the formula (I) or a salt thereof. In the formula (I), W represents —NR1R2 or —N+R11R12R13(Z−), R1 and R2 each independently represent H or an optionally substituted C1-5 alkyl group, R11, R12 and R13 each independently represent an optionally substituted C1-5 alkyl group, Z− represents an anion, X represents an optionally substituted C2-6 alkylene group, RA and RB each independently represent an optionally substituted C1-17 alkyl group, an optionally substituted C3-17 alkenyl group, an optionally substituted C15-17 alkadienyl group, —R3—C(O)O—R4 or —R3—OC(O)—R4, RC represents —R3—C(O)O—R4 or —R3—OC(O)—R4, R3 represents an optionally substituted C1-16 alkylene group, an optionally substituted C4-16 alkenylene group or an optionally substituted C7-16 alkadienylene group, and R4 represents H, an optionally substituted C1-18 alkyl group, an optionally substituted C3-18 alkenyl group or an optionally substituted C15-18 alkadienyl group.

METHOD FOR GROWTH OF AKKERMANSIA MUCINIPHILA COMPRISING ADMINISTERING PLATINUM NANOPARTICLES

Resumen de: US2025195563A1

This invention is to provide the novel composition that grows Akkermansia muciniphila in the intestinal microflora. The composition for the growth of Akkermansia muciniphila containing platinum nanoparticles as an active ingredient.

LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO PERIPHERAL BLOOD MONONUCLEAR CELLS, AND METHOD FOR DELIVERING NUCLEIC ACID TO PERIPHERAL BLOOD MONONUCLEAR CELLS USING SAME

Resumen de: US2025195429A1

The present invention provides lipid nanoparticles for delivering nucleic acid to peripheral blood mononuclear cells that can improve the efficiency of nucleic acid delivery to peripheral blood mononuclear cells, and a method for delivering nucleic acid to peripheral blood mononuclear cells by using same. Lipid nanoparticles for use in delivering a nucleic acid to a peripheral blood mononuclear cell, containing an ionic lipid represented by the formula (1), a phospholipid that is 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups have not less than 20 carbon atoms and at least one of the acyl groups is an alkenoyl group, cholesterol, and a dimyristoylglycerol PEG represented by the formula: CH2(OR6)—CH(OR7)—CH2(OR8) (symbols in the formula are as described in the specification), and a method for delivering a nucleic acids to a peripheral blood mononuclear cell by using same.

LIPID PARTICLE, COMPOSITION CONTAINING LIPID PARTICLE, KIT CONTAINING LIPID PARTICLE, AND ACTIVE AGENT DELIVERY METHOD USING LIPID PARTICLE

Resumen de: US2025195430A1

Provided are a lipid particle with high biodegradability, high biocompatibility, a high active agent introducibility, low cytotoxicity, and the like, a composition and a kit which use the lipid particle, and a method of delivering an active agent to a cell.The lipid particle according to the present embodiment comprises:a compound represented by the following Formula (a),Mal-La1-(OCH2CH2)na—O-La2Ra2  (a)(in the formula,Mal is a maleimide group,La1 is an unsubstituted hydrocarbon group, or a substituted hydrocarbon group,La2 is a trivalent hydrocarbon group that does not contain phosphorus,Ra's are a hydrocarbon group containing at least one ester bond at a predetermined position, andna is a number of 1 or more); andan active agent.

PEPTIDE-BASED PHOSPHATE BINDER FOR THE TREATMENT OF HYPERPHOSPHATEMIA

Resumen de: US2025195687A1

Provided herein are silica nanoparticles conjugated to a phosphate binding hexapeptide (PBH) via a linker amino acid residue and methods of making the same. Further provided are compositions including the nanoparticles and uses thereof in the treatment of hyperphosphatemia.

CONTINUOUS SPIN FREEZE-DRYING OF NUCLEIC ACID CONTAINING COMPOSITIONS

Resumen de: US2025195437A1

The present invention relates to the field of freeze-drying compositions, in particular nucleic acid containing compositions. More specifically, the present invention relates to freeze-dry nucleic acid containing compositions using a method of continuous spin freezing and continuous spin drying (sublimation and desorption) the composition. The invention further relates to a nucleic acid containing composition by making use of the method according to the invention.

POLYMER-COATED NANOPARTICLES AND PREPARATION METHOD THEREFOR

Resumen de: US2025195444A1

Polymer-coated nanoparticles and a preparation method therefor. The structural makeup of the polymer nanoparticles is: a hydrophilic aggregate inner core and a polymer molecular material coating containing a polyoxyethylene structural unit. The hydrophilic aggregate inner core comprises the following preparatory raw materials: a cationic component and an anionic component, the cationic component being a cation, a compound which can be ionized into a cation, or a composition thereof, and the anionic component being an anion, a compound which can be ionized into an anion, or a composition thereof.

NOVEL BIONIC NANOSPHERE M@P-WI AND ITS PREPARATION METHOD AND APPLICATION

Resumen de: US2025195447A1

A novel biomimetic nano-sphere M@P-WI includes PLGA nanoparticles and the membrane of breast cancer EO771 cells. The PLGA nanoparticles are encapsulated within the membrane of breast cancer EO771 cells, and IR780 and DDR2 inhibitor WRG-28 are embedded in the PLGA nanoparticles. A method for preparing and applying the novel biomimetic nano-sphere M@P-WI is also provided. The method utilizes the aforementioned novel biomimetic nano-sphere M@P-WI, to trigger the conversion of light into heat energy upon near-infrared laser irradiation. This “burns” the tumor and induces specific immune responses within the body, inhibiting tumor recurrence and metastasis. Under the action of WRG-28, it promotes apoptosis of cancer-associated fibroblasts (CAF), reduces the remodeling of tumor extracellular matrix microenvironment, enhances the distribution of nanomaterials within the tumor, and restricts the invasiveness of breast cancer cells. With laser irradiation, the photosensitizer exhibits its maximum efficacy, achieving complete elimination of TNBC rich in extracellular matrix.

ANTI-HUMAN PD-Ll AND TLR7 DOUBLE-TARGETING NANOBODY CONJUGATE DRUG AND USE THEREOF IN RESISTING TUMOR

Resumen de: US2025197503A1

An anti-human PD-L1 nanobody and use thereof, and an anti-human PD-L1 and TLR7 double-targeting nanobody conjugate drug, a preparation method therefor and use thereof are provided. Specifically, provided are use and a solution of an anti-human PD-L1 nanobody and a derivative protein thereof for anti-tumor treatment, and also provided are design, preparation, and identification solutions for a novel anti-human PD-L1 and TLR7 double-targeting nanobody drug conjugate and a derivative molecule thereof and an effect thereof in anti-tumor treatment. The anti-human PD-L1 and TLR7 double-targeting nanobody drug conjugate can exert significant anti-tumor efficacy.

LONG-LASTING ANTIMICROBIAL COMPOSITIONS CONTAINING CATIONIC ACTIVE AGENTS AND ANIONIC EXCIPIENTS AND USES

Nº publicación: US2025195445A1 19/06/2025

Solicitante:

UNIV FEDERAL DE MINAS GERAIS UFMG [BR]
2HEAL INDUSTRIA E COMERCIO DE PRODUTOS QUIM PARA USO INDUSTRIAL LTDA [BR]
Universidade Federal de Minas Gerais - UFMG,
2Heal Ind\u00FAstria e Com\u00E9rcio de Produtos Qu\u00EDmicos Para Uso Industrial LTDA

Resumen de: US2025195445A1

This invention refers to long-lasting antibacterial compositions with a broad spectrum of activity, including bactericidal, bacteriostatic, virucidal, virustatic, germicidal, algicidal, fungicidal, and fungistatic activities. These compositions can be used for the production of topical formulations or for environmental treatment, surface disinfection, or dental use. The composition can be in the form of a solution, a moist gel, xerogel, aerosol, spray, polymeric system, or solid state. Specifically, the invention refers to compositions, such as aqueous or alcoholic solutions, or even in gel or powder form, with antibacterial activity. These compositions contain a cationic active (chlorhexidine digluconate, quaternary ammonium, or cetil pyridine) nanoencapsulated in cyclodextrin (alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, hydroxymethyl beta-cyclodextrin, or hydroxypropyl beta-cyclodextrin), which may optionally include alkyl or aryl group insertions, at a molar ratio of 1:1 to 1:4. These compositions also include anionic excipients, as well as humectants, stabilizers, sequestering agents, surfactants, preservatives, or thickeners. Preferably, they include the anionic surfactant sodium lauryl sulfate or the anionic thickener carbomer.